Altered Cerebral Blood Flow One Month after Systemic Chemotherapy for Breast Cancer: A Prospective Study Using Pulsed Arterial Spin Labeling MRI Perfusion

Kelly N. H. Nudelman1,2,3, Yang Wang1,4,5, Brenna C. McDonald4,5,6, Susan K. Conroy3, Dori J. Smith3, John D. West3,4, Darren P. O’Neill3,4, Bryan P. Schneider1,5,6, Andrew J. Saykin1,3,4,5*

1 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 2 Training in Research for Behavioral Oncology and Cancer Control Program, Indiana University School of Nursing, Indianapolis, Indiana, United States of America, 3 Center for Neuromaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 4 Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 5 Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 6 Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

Abstract

Cerebral structural and functional alterations have been reported after chemotherapy for non-CNS cancers, yet the causative mechanism behind these changes remains unclear. This study employed a novel, non-invasive, MRI-based neuroimaging measure to provide the first direct longitudinal measurement of resting cerebral perfusion in breast cancer patients, which was tested for association with changes in cognitive function and gray matter density. Perfusion was measured using pulsed arterial spin labeling MRI in women with breast cancer treated with (N = 27) or without (N = 26) chemotherapy and matched healthy controls (N = 26) after surgery before other treatments (baseline), and one month after chemotherapy completion or yoked intervals. Voxel-based analysis was employed to assess perfusion in gray matter; changes were examined in relation to overall neuropsychological test performance and frontal gray matter density changes measured by structural MRI. Baseline perfusion was not significantly different across groups. Unlike control groups, chemotherapy-treated patients demonstrated significantly increased perfusion post-treatment relative to baseline, which was statistically significant relative to controls in the right precentral gyrus. This perfusion increase was negatively correlated with baseline overall neuropsychological performance, but was not associated with frontal gray matter density reduction. However, decreased frontal gray matter density was associated with decreased perfusion in bilateral frontal and parietal lobes in the chemotherapy-treated group. These findings indicate that chemotherapy is associated with alterations in cerebral perfusion which are both related to and independent of gray matter changes. This pattern of results suggests the involvement of multiple mechanisms of chemotherapy-induced cognitive dysfunction. Additionally, lower baseline cognitive function may be a risk factor for treatment-associated perfusion dysregulation. Future research is needed to clarify these mechanisms, identify individual differences in susceptibility to treatment-associated changes, and further examine perfusion change over time in survivors.

Introduction

Breast cancer treatment has made great strides, leading to an overall five-year survival rate of 89% according to SEER [1]. Given this high survival rate, resulting side effects are an area of increasing concern. Cognitive dysfunction in particular has been associated with breast cancer, chemotherapy, radiation, and anti-estrogen treatments, underscoring the need to clarify the mechanisms of disease and treatment effects on cognition [2–15]. Neuroimaging has been used to measure structural and functional effects of cancer and chemotherapy treatment, including treatment-associated frontal gray matter density (GMD) decrease in breast cancer patients [16–18]. However, characterization of the full spectrum of cerebral alterations associated with chemotherapy is far from complete; one novel area of investigation is the effect of chemotherapy on resting cerebral perfusion using pulsed arterial spin labeling (PASL) magnetic resonance imaging (MRI). PASL is a noninvasive advanced technique capable of
measuring blood flow by using magnetically labeled arterial blood water as an endogenous contrast tracer. This technique can provide quantitative, stable, and physiologically meaningful images [19]. It has been shown to be well-suited to longitudinal studies of cerebral perfusion in healthy and diseased individuals, or as a surrogate marker of metabolism [20]. Based on previous prospective breast cancer studies, observed GMD decrease post-treatment suggests the likelihood of accompanying hypoperfusion; however, patterns of increased and decreased activation observed during cognitive task performance post-treatment might indicate the presence of hyperperfusion as well [16–18,21–22]. To test these competing hypotheses, we conducted the first controlled prospective study of cerebral perfusion in breast cancer patients treated with (Ctx+) and without (Ctx−) standard-dose chemotherapy and healthy controls (HC) using PASL MRI. We predicted that the Ctx+ group would evidence statistically significant changes in brain perfusion compared to the HC and Ctx− control groups post-treatment, in response to or in order to compensate for chemotherapy-induced cellular, vascular, or other tissue damage, and that this change would correlate with cognitive performance. Additionally, we analyzed perfusion changes for associations with previously reported frontal GMD change to investigate the functional independence of these measures and underlying mechanisms [18].

**Methods**

**Ethics Statement**

All participants gave written informed consent according to the Declaration of Helsinki under a protocol approved by the Indiana University Institutional Review Board.

**Overall Study Design**

This manuscript focuses on a subset of data from a prospective, longitudinal investigation of cancer and treatment-related cognitive effects which includes a comprehensive study protocol of neuroimaging, neurocognitive, and behavioral assessments as well as biomarker investigation. Other aspects of this and a related
cohort have previously been reported [17,18,21,23]. In brief, study participants include Ctx+ and Ctx−, female breast cancer patients and demographically matched HC. For Ctx+ patients, all study measures were acquired at baseline (after surgery but before radiation, chemotherapy, and/or anti-estrogen treatment), approximately one month after chemotherapy treatment completion, and approximately one year later. These time points were chosen to allow examination of both sub-acute and longer-term effects of treatment, with a particular focus on the effects of chemotherapy. Ctx− patients and HC were studied at yoked intervals (see Table 1). In addition to the PASL and T1 sequences examined for this report, the detailed MRI examination included PD/T2 and FLAIR structural sequences, working and episodic memory functional MRI tasks, magnetic resonance spectroscopy, and diffusion tensor imaging. Neurocognitive assessment included a targeted research battery with emphasis on episodic memory and executive functioning, as well as measures briefly assessing other neuropsychological domains (e.g., general intellectual ability, language, attention, processing speed, visuospatial and motor skills, etc.). Self-report measures included demographic and medical information, treatment sequelae, self-perceived cognition, mood and anxiety, and diet and lifestyle factors. Finally, blood samples were acquired for routine labs, genetic analyses, and banked for future investigation of potential biomarkers. Blood work was typically acquired in the early morning, while other study measures were acquired over the course of one or two study visits depending on participant preference. MRI scanning was conducted prior to cognitive assessment whenever possible, though timing of study measures varied depending on scheduling availability.

Participants

The study cohort consisted of 27 Ctx+ patients, 26 Ctx− patients, and 26 HC. Only patients with non-invasive (stage 0) or non-metastatic invasive (stages I, II, or III) disease were included; additional exclusion criteria for all participants included prior cancer, substance abuse, and other medical, neurological, and psychiatric risk factors which might affect cerebral structure or function, as described in McDonald et al., 2013 [18]. Based on these criteria, 213 individuals were determined to be ineligible during phone screening. Another 15 individuals were excluded after enrolling in the study due to subsequent determination of ineligibility (e.g., tissue expanders, claustrophobia, etc.), withdrawal, or loss to follow-up, and 18 more individuals were excluded from this analysis due to lack of relevant data or scan quality, yielding 79 eligible participants with required data.

All Ctx+ patients were treated with common standard-dose chemotherapy regimens. Eight neoadjuvant chemotherapy patients’ baseline measures were completed before surgery as well as chemotherapy; these individuals did not differ significantly from the other Ctx+ patients for any demographic factors, depression, or anxiety. Patients were recruited via the Indiana University Melvin and Bren Simon Cancer Center recruitment core and affiliated clinical practices. Demographically matched healthy controls were recruited via community advertisements.

Demographic and treatment characteristics are summarized in Table 1. The Center for Epidemiologic Studies-Depression Scale (CES-D) and the State Trait Anxiety Inventory-State subscale (STAI-S) were used to measure depressive symptoms and anxiety at each visit [24,25]. Self-reported caffeine consumption on scan days was also obtained. Demographic and treatment variables were assessed for statistical significance using SPSS 19 (SPSS Statistics 19, IBM Corporation, Somers, NY), using ANOVA, general linear models, and chi-square analyses as appropriate.

MRI Acquisition

Scans were acquired on a Siemens Tim Trio 3T whole-body MRI scanner using a 12-channel receiver-only head coil. Subjects were scanned in a conscious resting state with closed eyes. Cerebral perfusion measurements were obtained using a previously published scan protocol [19]. Briefly, a Q2TIPS PASL sequence using the PICORE labeling scheme was applied. Utilizing a 10 cm labeling region with 25 mm spacing from the distal edge of the labeled region to the image section, an adiabatic inversion pulse for labeling was followed by optimized inversion time delays $T_1 = 700$ ms and $T_2 = 1800$ ms, chosen so as to minimize intravascular signal intensity at 3T. Images were acquired using a gradient-echo single shot EPI readout, with acquisition parameters: TR/TE = 3000/13 ms, FOV = 224 mm, and matrix = 64×64. The imaging region consists of 16 contiguous ascending axial slices of 7 mm thickness. Each perfusion measurement consists of 100 dynamic (50 control and label image pairs) plus one $M_0$ image (the equilibrium brain tissue magnetization used to normalize the difference perfusion map) with a scan time of approximately 5 minutes. The scanner’s built-in 3D online prospective acquisition correction (PACE) was used to minimize head motion artifact during acquisition. A high resolution T1-weighted magnetization prepared rapid gradient echo (MPRAGE) image and a high resolution EPI whole brain scan were acquired for subsequent reference and normalization; T2-weighted and fluid attenuated inversion recovery (FLAIR) sequences were also acquired to examine for incidental pathology.

Image Analysis

PASL scan processing was performed using previously published methods [14]. In brief, labeled images were subtracted from matched control images to create a perfusion-weighted time series; these were used to create quantitative regional perfusion maps for each scan, which were normalized to Montréal Neurological Institute (MNI) space in SPM8 (Wellcome Department of Cognitive Neuroscience, London, UK), resampled to 2 mm³ voxels, and smoothed with a FWHM kernel of 6×6×8 mm. Image analyses in SPM8 were run with and without age at baseline and scan-day caffeine consumption as covariates given previous findings of perfusion variance [26,27]. However, inclusion of these variables is not shown as groups were balanced and these variables did not significantly alter any results.

A general linear model approach was utilized to conduct statistical parametric mapping on a voxel-by-voxel basis in SPM8. To specifically examine perfusion in gray matter, the Pick Atlas gray matter mask was used as an explicit mask in all analyses [28]. MRI image acquisition and analysis of GMD was performed as described in McDonald et al., 2013 [18].

Baseline analyses using a random effects model were performed to identify voxels with initial perfusion differences between groups. Weighted contrast vectors were entered for each group in the design matrix as described in McDonald et al., 2013 [18]. To test for areas in which cancer patients showed hypoperfusion relative to controls at baseline, $-1$ was entered in the Ctx+ and Ctx− baseline columns, while 2 was entered in the control baseline column. Alternate directionality and other interactions were similarly tested. The voxel-wise critical significance threshold ($P_{	ext{unc}}$) was set to 0.001 uncorrected, with a minimum cluster extent (k) of 100 voxels for this and subsequent tests to reduce noise.

An unbiased F test of overall effects was performed to identify any statistically significant perfusion differences between groups and times. The cluster of voxels with the most significant perfusion difference was used to graph group-by-time contrast estimates and 90% confidence intervals. All groups were tested alone for
perfusion change over time using weighted contrast vectors. Based on these results, the Ctx+ group was analyzed for perfusion increase over time relative to HC in an interaction model, also using weighted contrast vectors.

**Perfusion and Cognition Analysis**

Due to the small cohort size, we chose to investigate cognition utilizing an overall neuropsychological performance test score (global score), generated by averaging scores for eight neuropsychological domains in a similar fashion as in Conroy et al., 2013 [29] and Ahles et al., 2008 and 2010 [3,4]. To discern whether chemotherapy was associated with a change in cognition, global score change was assessed for association with treatment group in SPSS 19 using a one-way ANOVA. Based on the results, global baseline score was chosen for testing with Ctx+ perfusion change. We extracted baseline and post-treatment cluster scores for the right precentral gyrus (area of significant increase in Ctx+ compared to HC) using MarsBar in SPM8, and subtracted baseline from post-treatment scores to obtain a change score for each Ctx+ individual [30]. Ctx+ perfusion change scores were tested for Pearson correlation with global baseline scores in SPSS.

**Perfusion and GMD Change Association Analysis**

To test for association of GMD and perfusion, we compared the previously identified frontal GMD change clusters with the more regionally diffuse pattern of change observed for perfusion. Association was only tested in the Ctx+ group, since only this group had statistically significant changes in both measures. To analyze this association, we extracted the two frontal clusters where significant GMD decreases occurred after chemotherapy using MarsBar in SPM8 and averaged them to obtain one GMD measure for each subject at each time point [30]. The measures at baseline were subtracted from the post-treatment measures, yielding a change score for each individual. These GMD change scores were used as the covariate of interest in a multiple regression testing for association with whole brain perfusion change. Perfusion change was measured by subtracting PASL baseline scans from post-treatment scans using the ImCalc utility in SPM8 to create new scans only including regions of change.

![Figure 1. Group-by-time analysis (F test). Surface rendering of perfusion differences from baseline to one month post-treatment for all groups (Pcrit = 0.001 uncorrected, k = 100). Colored areas indicate statistically significant changes between groups and/or times; red to yellow color scale indicates increasing statistical significance, with yellow areas indicating the most significant regions. doi:10.1371/journal.pone.0096713.g001](image1)

![Figure 2. Maximum perfusion change. Right postcentral gyrus perfusion signal from overall F test graphed by group and time (Red bars indicate 90% confidence intervals (C.I.)). Key: BL = baseline, 1 M = one month post-treatment. doi:10.1371/journal.pone.0096713.g002](image2)
### Table 2. Regional Perfusion Changes for the Overall F Test, All Groups by Times.

| x^a | y^a | z^a | k^b | T    | Z    | P_{FWE-corr}^c | Region description (for cluster peak) |
|-----|-----|-----|-----|------|------|----------------|---------------------------------------|
| 44  | −24 | 56  | 437 | 8.32 | 4.87 | 0.009         | R Postcentral G (BA3)                 |
| 16  | −58 | 54  | 112 | 7.91 | 4.72 | 0.018         | R Precuneus (BA7)                     |
| 48  | −70 | 2   | 268 | 7.78 | 4.67 | 0.022         | R M Temporal G (BA37)                |
| 42  | 0   | −48 | 183 | 7.74 | 4.65 | 0.024         | R Precentral G (BA6)                 |
| −10 | −46 | 50  | 264 | 6.39 | 4.10 | 0.217         | L Precuneus (BA7)                    |

^aMNI coordinates.
^bCluster extent.
^cPeak-level p value.

Key: R = Right, L = Left, G = Gyrus, BA = Brodmann Area, I = Inferior, M = Middle, S = Superior.

doi:10.1371/journal.pone.0096713.t002

### Table 3. Regional Perfusion Changes for Ctx+ Post-Treatment Increase.

| x^a | y^a | z^a | k^b | T    | Z    | P_{FWE-corr}^c | Region description (for cluster peak) |
|-----|-----|-----|-----|------|------|----------------|---------------------------------------|
| 46  | −22 | 56  | 673 | 5.32 | 5.09 | 0.012         | R Postcentral G (BA3)                 |
| 32  | −84 | 24  | 1464| 5.20 | 4.98 | 0.000         | R S Occipital G (BA19)                |
| 66  | −24 | 34  | 116 | 5.03 | 4.83 | 0.052         | R Postcentral G (BA2)                 |
| −14 | 12  | −10 | 119 | 4.27 | 4.14 | 0.540         | L Lentiform Nucleus                    |
| −6  | −86 | 26  | 425 | 4.26 | 4.14 | 0.059         | L Cuneus (BA19)                       |
| −6  | −64 | 56  | 207 | 4.22 | 4.10 | 0.282         | L Precuneus (BA7)                     |
| −16 | −94 | −16 | 101 | 4.20 | 4.08 | 0.612         | L I Occipital G (BA17)                |
| −54 | −18 | 54  | 128 | 4.07 | 3.96 | 0.507         | L Postcentral G (BA3)                 |

^aMNI coordinates.
^bCluster extent.
^cPeak-level p value.

Key: R = Right, L = Left, G = Gyrus, BA = Brodmann Area, I = Inferior, M = Middle, S = Superior.

doi:10.1371/journal.pone.0096713.t003
After multiple regression association testing of frontal GMD change with whole brain perfusion change in SPM8, again using the Pick Atlas gray matter mask, positive and negative associations were analyzed. Covarying for age did not significantly alter the results and is not reported. To graph GMD and perfusion, statistically significant perfusion change clusters from the positive association were extracted using MarsBar and averaged to one change score per individual; these were plotted against the GMD change measure. One individual’s perfusion and GMD scores were more than three standard deviations below the mean. Inclusion/exclusion of this individual’s scores did not alter the statistical significance of the findings, so these data points are excluded from the graphical presentation of the results.

Results

Demographic and Baseline Comparisons

Ctx+ patients had significantly higher stage disease than Ctx− patients (X² = 18.82, df = 3, P < 0.001), as expected given current treatment protocols, and most had not received either radiotherapy or hormone therapy by one month post-chemotherapy treatment. There were no other statistically significant demographic differences or group-by-time interactions with depression or anxiety symptoms (CES-D, STAI-S, Table 1). The second scan occurred on average six months after the baseline visit; interscan intervals did not differ significantly between groups (Table 1). Eight patients received neoadjuvant treatment; these individuals did not demonstrate statistically significant demographic differences or group-by-time interactions with depression or anxiety symptoms compared to adjuvant Ctx+, Ctx−, or HC groups.

Baseline comparisons indicated no significant between-group differences in perfusion.

Perfusion Change: Chemotherapy Group Hyperperfusion

An F test across all groups and both time points indicated statistically significant perfusion change over time, primarily in the right hemisphere (Figure 1, Table 2). The cluster of maximal change, located in the right postcentral gyrus, is presented for all groups and both time points (Figure 2). In this region, the Ctx+ group showed hyperperfusion at one month post-treatment relative to both comparison groups. For this and subsequent image analyses, results including MNI coordinates, cluster extents, multiple comparison-corrected P values, T and Z scores, and regions are presented in Tables 2–5.

To further elucidate group differences in change over time, each group was tested individually. Only the Ctx+ group had statistically significant perfusion change, demonstrating an increase in perfusion from baseline to one month post-treatment, primarily in superior and posterior brain regions (Figure 3, Table 3). To determine how much of this increase was statistically significantly different than controls, we analyzed group-by-time interactions; results indicated that the Ctx+ group perfusion increased relative to HC specifically in the right precentral gyrus after treatment, indicating that these patients had resting state hyperperfusion discernible by MRI compared to controls (Figure 4, Table 4). Table 6 lists mean perfusion for both time points as well as perfusion change for the right precentral gyrus cluster.

The eight neoadjuvant patients were not analyzed separately, as the study design was not powered to detect subgroup effects. However, in the neoadjuvant-treated participants the mean perfusion increase in the right postcentral gyrus was almost identical to that observed for the adjuvant Ctx+ participants and Ctx+ group as a whole. The three Ctx+...
### Table 5. Regional Perfusion Changes for Ctx+ Perfusion and GMD Positive Association.

| $x^*$ | $y^*$ | $z^*$ | $k^b$ | $T$   | $Z$   | $P_{FWE-corr}$ | Region description (for cluster peak)           |
|-------|-------|-------|-------|-------|-------|----------------|-----------------------------------------------|
| 12    | 18    | −24   | 578   | 10.13 | 6.33  | 0.006         | R Rectal G (BA11)                             |
| −50   | −60   | −22   | 153   | 9.71  | 6.20  | 0.317         | L Fusiform G (BA37)                           |
| 44    | 48    | −10   | 136   | 8.26  | 5.68  | 0.377         | R M Frontal G (BA11)                          |
| −4    | 50    | −24   | 285   | 7.61  | 5.43  | 0.084         | L Rectal G (BA11)                             |
| 22    | 44    | 50    | 513   | 7.34  | 5.31  | 0.011         | R S Frontal G (BA8)                           |
| −42   | −58   | 44    | 248   | 7.20  | 5.25  | 0.120         | L I Parietal Lobule (BA40)                     |
| 34    | −40   | 56    | 264   | 6.85  | 5.09  | 0.103         | R Postcentral G (BA40)                        |
| −8    | 58    | 40    | 255   | 6.71  | 5.03  | 0.112         | L S Frontal G (BA9)                           |
| −38   | 42    | 38    | 189   | 6.52  | 4.49  | 0.219         | L S Frontal G (BA9)                           |
| −48   | −58   | 44    | 114   | 6.10  | 4.73  | 0.470         | L I Parietal Lobule (BA40)                     |
| 38    | 64    | 12    | 608   | 5.92  | 4.64  | 0.005         | R M Frontal G (BA10)                          |
| 24    | −10   | −12   | 121   | 5.74  | 4.54  | 0.439         | R Amygdala                                    |
| −22   | −8    | 0     | 159   | 5.07  | 4.17  | 0.298         | L Lentiform Nucleus                            |

$^a$MNI coordinates.

$^b$Cluster extent.

$^c$Cluster-level $p$ value.

Key: R = Right, L = Left, G = Gyrus, BA = Brodmann Area, I = Inferior, M = Middle, S = Superior.

doi:10.1371/journal.pone.0096713.t005
patients who received anti-estrogen treatment in this interval also displayed a post-chemotherapy perfusion increase, though there was insufficient power for a formal assessment of hormonal effects or interactions. Given that only two Ctx+ patients received radiotherapy treatment during this interval, this factor is also unlikely to contribute significantly to the observed variation.

Chemotherapy-Associated Hyperperfusion and Cognition

To clarify the clinical significance of this perfusion increase, we assessed perfusion change for correlation with cognitive performance. Change in the global neuropsychological test score from baseline to post-treatment was not statistically significantly different between groups, although all groups showed an increase over time likely attributable to practice effects (Table 7). In the Ctx+ group, baseline global score was negatively correlated ($r = -0.629, P<0.001$) with right precentral gyrus perfusion change from baseline to one month (Figure 5), indicating that individuals with lower baseline cognitive performance showed greater perfusion increase over time.

Perfusion and GMD Association

Because the chemotherapy-associated perfusion increase was not located in the frontal regions where GMD decrease was observed by McDonald et al., 2013 [18], we hypothesized that these effects might be independent. When the frontal GMD decrease was analyzed for association with whole brain perfusion change, we observed that there were statistically significant regions of bilateral frontal and parietal perfusion change positively correlated with GMD change (Figure 6, Table 5), indicating that decreased frontal GMD was associated with lower perfusion in these regions ($r = 0.553, P = 0.003$). However, if the frontal GMD decrease was associated with the hyperperfusion observed in Ctx+ patients, we would expect to see significant negative association in the superior and posterior regions. In this analysis there were no statistically significant regions of negative association, supporting our hypothesis that these are independent effects.

Discussion

This is the first prospective, longitudinal study documenting the effects of chemotherapy on resting cerebral perfusion in breast cancer patients. Given conflicting evidence from other measures of cerebral effects of chemotherapy, we investigated two competing hypotheses, chemotherapy-induced hypo- or hyper-perfusion. Although previous evidence suggests that aspects of the cancer disease process and/or host factors in cancer patient may induce cerebral structural and functional alterations, in the present study there were no statistically significant between-group perfusion differences at baseline [18,21,29–33]. This initial observation suggests that breast cancer itself is not associated with changes in cerebral perfusion. Although requiring replication and possibly specific to the present cohort, the lack of baseline differences suggests that treatment-associated findings are unlikely to be confounded by cancer-induced changes. This is important to note, as it may suggest that perfusion is a more specific indicator of cerebral alterations after chemotherapy, as other functional neuroimaging measures have shown differential alterations both prior to and after chemotherapy.

Although perfusion and metabolism are normally coupled, a previous cerebral resting state metabolic study using fluorodeoxyglucose $[^{18}F]$ positron emission tomography (PET) by Silverman et al., 2007 did not find significant differences between control and adjuvant chemotherapy-treated groups, though they did identify a significant correlation between metabolism and the Rey-Osterrieth Complex Figure delayed recall performance in chemotherapy-treated subjects [22]. They also found differential perfusion in Ctx+ group patients compared to controls during a functional $[^{15}O]$ PET study. Using functional MRI, McDonald and colleagues found differential activation in Ctx+ group patients, further supporting the idea that chemotherapy may alter perfusion and activation [21]. Thus it appears that PET and MRI may be complementary detection methods for perfusion and metabolic changes in response to chemotherapy. This new PASL data adds another perspective to prior findings, indicating that perfusion is altered in the resting state as well as during tasks,
and may be related to previously identified metabolic, cognitive, and structural changes in breast cancer patients.

To date, the precise mechanisms underlying chemotherapy-induced cognitive alterations are unknown. In addition to possible direct neurotoxic injury, several pathways that could influence cerebral structure and function have been posited as potentially affected by chemotherapy, including immune response, DNA repair, oxidative stress, and altered hormone levels or signaling, all of which may be genetically modulated [34–36]. Although only small amounts of chemotherapeutic agents have been measured in the brain, this may still be enough to provoke various cellular responses including inflammation and oxidative stress, less effective DNA repair, and possibly cell death, leading to structural and functional alterations and cognitive dysfunction [37–41]. All chemotherapy drugs utilized in this cohort are alkylating agents, antracyclines, platinating agents, or taxanes; these antineoplastic agents target various aspects of DNA repair and cell cycle division, and cause apoptosis. A systemic response to cell death could include several of the mechanisms listed above, and have widespread indirect cerebral effects, such as hyperperfusion. Interestingly, paclitaxel and docetaxel have been shown to have peripheral anti-angiogenic effects, and doxorubicin and paclitaxel have been associated with vascular toxicity [42–44]. Since all but one patient received paclitaxel or docetaxel, and only one patient in the Ctx+ group was on bevacizumab during the study, we could not draw any conclusions on the effects of anti-angiogenesis on perfusion; however, the individual receiving bevacizumab did experience increased perfusion post-treatment, consistent with other Ctx+ patients. The study was also not powered to examine any specific vascular toxicity related to doxorubicin or paclitaxel; this will be an important factor to consider in future studies. Although chemotherapy-altered estrogen signaling is still a possible causal mechanism, changes were likely not related to anti-estrogen treatments or aromatase inhibitors, since only three individuals out of 27 in the Ctx+ group were taking these types of medications at one month post-treatment [45]. Although this study was not powered to assess these individuals as a separate group, they did display hyperperfusion that was greater than that observed for the Ctx− or HC groups, though not as large as the Ctx+ group increase as a whole. Based on this evidence, we conclude that anti-estrogen or aromatase inhibitors are unlikely to contribute significantly to the observed hyperperfusion. Radiotherapy was similarly different between groups, with nearly all Ctx+ patients receiving this treatment following the one month post-chemotherapy time point, whereas the majority of Ctx− received radiotherapy before this time point. This emphasizes the specificity of the chemotherapy effect on cerebral perfusion, as radiotherapy is unlikely to confound these results. Finally, caffeine consumption is known to influence cerebral blood flow. We only obtained general self-reported caffeine consumption on scan days, and so were not powered to do a detailed analysis of the variance accounted for by this measure; however, basic self-reported caffeine consumption was not significantly different between groups, suggesting that this was not a confounding factor for this analysis.

Our observation that the statistically significant Ctx+ increase in cerebral perfusion was negatively correlated with baseline neuropsychological test performance suggests that baseline cognitive reserve may indicate an indirect protective mechanism; perhaps the Ctx+ post-treatment perfusion increase is an unsuccessful compensatory mechanism that is most pronounced in individuals with lower cognitive ability [4]. Future research should focus on identifying the biological mechanism driving the potential protective effect of baseline cognitive performance/reserve.

The statistically significant pre- and postcentral gyri regions of chemotherapy-associated cerebral perfusion increase reported here were independent of frontal GMD decreases noted in this cohort. However, bilateral frontal and parietal decreases in perfusion were observed that correlated with GMD decreases. These regional perfusion alterations may be influenced by different mechanisms. This is supported by previous investigations...

---

**Table 6. Right Precentral Gyrus Perfusion Group Means.**

|                  | Ctx+ (N = 27) | Ctx− (N = 26) | HC (N = 26) | p* |
|------------------|---------------|---------------|-------------|----|
| Cluster Perfusion: Baseline | 35.0 (10.7), (18.1–53.7) | 33.9 (13.3), (2.5–57.5) | 35.9 (10.4), (18.1–57.7) | 0.821 |
| Cluster Perfusion: 1 M | 49.7 (18.9), (21.5–96.6) | 38.8 (16.5), (−2.6–81.7) | 33.9 (10.6), (12.8–56.8) | 0.002 |
| Cluster Perfusion: Changeb | 15.0 (16.7), (−9.6–57.2) | 4.9 (14.7), (−22.1–33.9) | −2.0 (9.0), (−20.9–11.5) | 0.000 |

Values are Mean (Standard Deviation), (Range). 1 M = one month post-treatment.

*aSignificance, one way ANOVA with treatment group.

*bChange = 1 M – Baseline.

doi:10.1371/journal.pone.0096713.t006

---

**Figure 5. Ctx+ baseline cognitive performance and perfusion change correlation.** Individual baseline global neuropsychological test performance (x-axis) graphed with right precentral gyrus perfusion cluster (statistically significant increase in Ctx+ vs. HC from baseline to post-treatment) change from baseline to one month post-treatment, indicating a significant negative correlation of baseline cognition with perfusion change.

doi:10.1371/journal.pone.0096713.g005
in Alzheimer’s disease suggesting that PASL and MRI GMD measures are complementary and have similar sensitivity; consequently if these measures were associated we would likely have detected this in our study [46]. Assuming different mechanisms are involved, one reason for the lack of correlation could be the influence of individual demographic and risk factors on susceptibility; for instance, it may be that some individuals may have genetic polymorphisms impairing drug clearance, leading to toxicity, cell death, and hypoperfusion, while others are physiologically predisposed to inflammation, which might lead to hyperperfusion. The observed lack of association indicates that there are some individuals who experience both hyperperfusion and decreased GMD post-treatment; future studies should examine whether these two measures have additive relationships with cognitive performance or complaints, which may perhaps explain why only a subgroup of breast cancer survivors appear to experience long-term cognitive dysfunction.

Further studies should also examine possible correlations of perfusion with other imaging methods, in order to further clarify the mechanistic basis of chemotherapy-induced cognitive alterations, with the long-term goal of developing preventative measures or treatments targeting these effects. While some cognitive alterations have been observed in survivors of breast cancer years after treatment, other studies show patient improvement by one year post-treatment [4,17,21,47]. If brain changes such as those observed in this study persist, they may be contributing to long-term cognitive sequelae, prioritizing perfusion as a target for therapeutic measures [48]. Future studies should utilize multimodal imaging and long-term prospective designs to clarify the mechanistic basis and persistence of this adverse effect, to help determine the focus of therapeutic efforts and pharmaceutical intervention in this patient population. Additional research could also use animal models to investigate the association of mechanisms such as direct neurotoxicity and immune response with neuroimaging measures; findings from such studies could provide important cues for therapeutic efforts.

This first study of cerebral perfusion in a prospective cohort of breast cancer patients and healthy controls provides evidence that chemotherapy is associated with alterations in cerebral perfusion, independent of cancer effects. We found statistically significant hyperperfusion in superior and posterior regions after chemotherapy, which was not seen in patients who did not receive chemotherapy or controls. While this hyperperfusion was independent of frontal GMD decrease after chemotherapy, regional frontal and parietal hypoperfusion post-treatment did correlate with GMD decreases in these patients. The regional dissociation between hyperperfusion and GMD reduction suggests the involvement of independent functional mechanisms, as well as potential influence of

---

**Table 7. Global Cognitive Performance.**

|                          | Ctx+ (N = 27)* | Ctx− (N = 25)* | HC (N = 26) | \( \rho \) |
|--------------------------|---------------|---------------|------------|-----|
| Global score: Baseline   | 0.1 (0.6), (−1.1–1.3) | 0.2 (0.6), (−1.6–1.0) | 0.0 (0.7), (−1.7–1.0) | 0.8 |
| Global score: 1 M        | 0.2 (0.6), (−1.0–1.4) | 0.3 (0.6), (−1.3–1.3) | 0.2 (0.7), (−1.8–1.3) | 0.8 |
| Global score change²     | 0.1 (0.2), (−0.2–0.9) | 0.2 (0.2), (−0.2–0.5) | 0.2 (0.2), (−0.1–0.8) | 0.6 |

Values are Mean (Standard Deviation), (Range). 1 M = one month post-treatment.

*Due to missing neuropsychological data, a global score could not be calculated for one Ctx+ individual at 1 M (1 M Ctx+ N = 26), as well as one Ctx− individual at either time point.

²Significance, one way ANOVA with treatment group.

²Change = 1 M – Baseline.

doi:10.1371/journal.pone.0096713.t007

---

**Figure 6. Perfusion and GMD positive association.** A) Surface rendering of positive association between frontal GMD decrease and bilateral frontal and parietal perfusion change; association does not overlap with regions of Ctx+ hyperperfusion. B) Frontal GMD decrease (x-axis) graphed with average of all positively associated clusters of perfusion change (y-axis); decreased GMD is associated with decreased primarily frontal perfusion. doi:10.1371/journal.pone.0096713.g006
Acknowledgments

The authors thank Kim Wagler-Ziner, PhD, the Indiana University-Melvin and Bren Simon Cancer Center recruitment core, and our oncology colleagues for their invaluable assistance with patient recruitment. We also thank Michele A. Beal, RT, and Courtney R. Robbins, RT for their assistance with scan acquisition. Finally, we are very grateful to our participants for their time and effort; this research would not have been possible without their willingness to participate during a particularly challenging time in their lives.

Author Contributions

Conceived and designed the experiments: BCM AJS. Performed the experiments: DJS DPO. Analyzed the data: KN YW BCM SKC JDW BPS AJS. Contributed reagents/materials/analysis tools: YW JDW AJS. Wrote the paper: KN YW.

References

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2012) SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Available: http://seer.cancer.gov/csr/1975_2009_ pop9/.

2. Agrawal K, Oumi S, Mortimer JE, Pal SK (2010) Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 67: 209–214.

3. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, et al. (2008) Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110: 143–152.

4. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, et al. (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28: 4434–4440.

5. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S (2009) Cognitive effects of chemotherapy post-treatment in breast cancer patients 1 year after treatment. Psychooncology 18: 134–143.

6. Falletti MG, Sannipillo A, Maruff P, Weil I, Phillips KA (2005) The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 59: 60–70.

7. Fan HG, Houede-Tchen N, Yi QL, Chemerynsky I, Downie FP, et al. (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23: 8025–8032.

8. Holohan KN, Von Ah D, McDonald BC, Saykin AJ (2013) Neuroimaging, cancer, and cognition: state of the knowledge. Semin Oncol Nurs 29: 280–287.

9. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, et al. (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115: 1776–1783.

10. Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116: 113–123.

11. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, et al. (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100: 2299–2329.

12. Bender CM, Sereika SM, Berga SL, Vogel VG, Brusky AM, et al. (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15: 422–430.

13. Schilder CM, Eggers PC, Seynave C, Lann SC, Boegerd W, et al. (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-safe study. Acta Oncol 48: 76–85.

14. Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30: 3675–3691.

15. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakanoto T, et al. (2007) Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109: 146–156.

16. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123: 819–828.

17. McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30: 1117–125.

18. Wang Y, Saykin AJ, Pfeiffer J, Lin C, Mosier KM, et al. (2011) Regional cerebrovascular reactivity of pulsed arterial spin labeling perfusion imaging at 3T. Neuroimage 54: 1108–1115.

19. Detre JA, Wang J, Wang Z, Rao H (2009) Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 22: 348–355.

20. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2012) Alterations in Brain Activation during Working Memory Processing Associated with Breast Cancer and Treatment: A Prospective Functional MRI Study. J Clin Oncol 30: 2505–2508.

21. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, et al. (2007) Altered frontoocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103: 305–314.

22. Conroy SK, McDonald BC, Ahles TA, West JD, Saykin AJ (2013) Chemotherapy-induced amnestic: a prospective study of brain activation changes and neurocognitive correlates. Brain Imaging Behav 7: 491–508.

23. Raaff LF (1977) The CENS-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1: 385–401.

24. Spielberger CD (1983) State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, Inc.

25. Wierenga CE, Clark LR, Dev SJ, Shin DD, Jurick SM, et al. (2013) Interaction of age and APOE genotype on cerebral blood flow at rest. J Alzheimers Dis 34: 921–935.

26. Wang DJ, Chen Y, Fernandez-Seara MA, Dette JA (2011) Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 337: 359–366.

27. Mählmann JA, Lauriatti PJ, Kraft RA, Burdette JH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of MRJ data sets. NeuroImage 19: 1233–1239.

28. Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, et al. (2013) Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 137: 493–502.

29. Brett M, Aljabare T, van RJ, JB (2002) Region of interest analysis using an SPM toolbox. 8th International Conference on Functional Mapping of the Human Brain. Sendai, Japan: NeuroImage.

30. Cimpanich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, et al. (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32: 324–331.

31. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A (2012) Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol 34: 543–560.

32. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A (2011) Prechemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an fMRI study. Front Hum Neurosci 5: 122.

33. Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7: 192–201.

34. Ahles TA, Conroy SK, McDonald BC (2003) Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8: 201–216.

35. Walker CH, Drew BA, Antoun JW, Kalies H, Beckman BS (2012) Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest 30: 135–148.

36. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5: 22.

37. Gangloff A, Huesel WA, Kesner AL, Kiesewetter DO, Pio BS, et al. (2005) Estimation of pacitaxel biodistribution and uptake in human-derived xenografts in vivo with [13N]docetaxel PET. J Nucl Med 46: 1866–1871.

38. Ginos JJ, Cooper AJ, Dhawan V, Lai JC, Strother SC, et al. (1997) [13N]Cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28: 1844–1852.

39. Troy L, McFarland K, Littman-Power S, Kelly BJ, Walpole ET, et al. (2000) Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 11: 59: 60–70.
44. Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14: 13–19.
45. Pachnicki JP, Cazeczko NG, Tsou F, Cavalcanti TS, Malafaia AB, et al. (2012) Immunohistochemical evaluation of estrogen and progesterone receptors of pre and post-neoadjuvant chemotherapy for breast cancer. Rev Col Bras Cir 39: 86–92.
46. Dashjants T, Yoshiura T, Hiwatashi A, Yamashita K, Monji A, et al. (2011) Simultaneous arterial spin labeling cerebral blood flow and morphological assessments for detection of Alzheimer’s disease. Acad Radiol 18: 1492–1499.
47. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, et al. (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485c-493.
48. de Ruiter MB, Reneman L, Booger W, Veltman DJ, van Dam FS, et al. (2011) Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 32: 1206–1219.
49. Barona A, Reynolds C, Chastain R (1984) A demographically based index of pre-morbid intelligence for the WAIS-R. J Consult Clin Psych 52: 885–887.